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Identity 
Other names: BC032224; J03278: M21616; JTK12; 
PDGFR; CD140B; PDGFR1; PDGF-R-beta 
HGNC (Hugo): PDGFRB 
Location: 5q31-q32 
Local order: MXI1 (MAX-interacting protein 1) is 
more telomeric. XPNPEP1 (X-prolylaminopeptidase 1) 
is more telomeric. 
 




23 exons spanning 149.5 Mb on 5q31-q32. 
Transcription is from telomere to centromere. 
Transcription 
1 transcript in RefSeq encoding NP_002600. 1 
transcript in EnsEMBL encoding ENSP00000261799. 
Protein 
Note 
PDGFRB; Beta platelet-derived growth factor receptor 
[Precursor]. 
Description 
Beta platelet-derived growth factor receptor precursor 
(PDGF-R-beta) (CD140b antigen). 
 
 
Genomic structure of PDGFRB. Black boxes indicate exons, small ones indicate untranslated exons. 
 
Schematic representation of PDGFRB. Ig-like domains: extracellular immunoglobulin-like domains involved in protein-ligand interaction, 
TM: transmembrane domain, Split-TK domain: RTK class III cytoplasmic kinase domain with an insertion of 70 to 100 hydrophilic 
residues. 










Type I membrane protein. 
Function 
Is receptor that binds specifically to PDGFB and has a 
tyrosine-protein kinase activity. Is a cell surface 
tyrosine kinase receptor for members of the platelet-
derived growth factor family (PDGF). The 
PDGFR/PDGF system includes two receptors 
(PDGFRA and PDGFRB) and four ligands (PDGFRA, 
B, C and D). The receptors PDGFRA and PDGFRB are 
related in sequence and both are members of the class
III subtype of receptor tyrosine kinases (RTKs). Other 
class III RTKs are CSF1R, KIT and FLT3. Mature 
PDGFRB consist of 1067 amino acids and can bind 
strongly to PDGF-BB and -DD homodimers, but 
weakly to AB heterodimers and not to PDGF-AA 
homodimer. The different ligands seem to induce 
different signals. 
Homology 
PDGFRB presents homology in several species. It also 
belongs to GROWTH FACTOR RECEPTOR 









Some rare gene fusions involving PDGFRB have been 
described in several patients with chronic 
myeloproliferative disorders (CMPD), 
myelodysplastic/myeloproliferative syndromes 
(MDS/MPD) and AML, often associated with 
eosinophilia and splenomegaly. Transformation to 
acute leukemia has been observed in a minor 




Described in an 11 month old girl with 














PDGFRB fusion partner unpublished. Translocation 












PDGFRB fusion partner unpublished. 
Disease 










PDGFRB fusion partner unpublished. 
Disease 

































Described in five cases with atypical CML. 
Prognosis 









Associated to atypical CML, AML, chronic 
myelomonocytic leukaemia (CMML), chronic 












Described in a patient with AML and a 
t(7;11)(p15;p15) at initial diagnosis, who relapsed with 
a prominent eosinophilia, hepatosplenomegaly and 











Described in a patient with a chronic 
myeloproliferative disorder with eosinophilia. 
Prognosis 









Described in a patient with a chronic 
myeloproliferative disorder with peripheral blood 
monocitosis. 
Prognosis 




5' KIAA1509-PDGFRB 3'. 
Abnormal protein 
5' KIAA1509-PDGFRB 3'. 
t(5;15)(q33;q22) 
Disease 
Described in a patient with a chronic 
myeloproliferative disorder with eosinophilia. 
Prognosis 
Imatinib mesylate responsive disease but the patient 















5' HCMOGT-PDGFRB 3' fusion described in an 18 
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